| 45.32 -1.62 (-3.45%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 56.64 | 1-year : | 66.16 |
| Resists | First : | 48.5 | Second : | 56.64 |
| Pivot price | 43.61  |
|||
| Supports | First : | 43.64 | Second : | 40.63 |
| MAs | MA(5) : | 45.18 |
MA(20) : | 43.79 |
| MA(100) : | 39.35 |
MA(250) : | 30.72 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 78.2 |
D(3) : | 75.5 |
| RSI | RSI(14): 56.1  |
|||
| 52-week | High : | 48.5 | Low : | 14.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EWTX ] has closed below upper band by 20.5%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 46.98 - 47.23 | 47.23 - 47.44 |
| Low: | 44.74 - 45.02 | 45.02 - 45.25 |
| Close: | 44.87 - 45.34 | 45.34 - 45.73 |
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Fri, 18 Sep 2026
Biotech Options Buzz: UTHR, NMRA, EWTX - Schaeffer's Investment Research
Sun, 13 Sep 2026
Edgewise Therapeutics Jumps As EDG-7500 Data Fuels Bullish Target Hike - StocksToTrade
Sat, 12 Sep 2026
Edgewise Therapeutics Stock Rises as JPMorgan Lifts Price Target - timothysykes.com
Wed, 02 Sep 2026
Four new employees receive stock awards from Edgewise - Stock Titan
Tue, 04 Aug 2026
Edgewise Therapeutics gains as investors weigh cash-rich reset and cardiovascular pipeline progress - Quiver Quantitative
Tue, 21 Jul 2026
Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 109 (M) |
| Shares Float | 74 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 111.8 (%) |
| Shares Short | 9,680 (K) |
| Shares Short P.Month | 10,070 (K) |
| EPS | -1.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.1 % |
| Return on Equity (ttm) | -38.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -158 (M) |
| Levered Free Cash Flow | -92 (M) |
| PE Ratio | -24.5 |
| PEG Ratio | 0 |
| Price to Book value | 10.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -31.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|